Analysts are saying that AbbVie could rise by 2030. Bullish on ABBV? Invest in AbbVie on SoFi with no commissions. If it’s your first time signing up for SoFi, you’ll receive up to $1,000 in stock when you first fund your account. Plus, get a 1% bonus if you transfer your investments and keep them there until December 31, 2025.
AbbVie Inc. (ABBV) is facing the same challenge as other pharmaceutical companies: developing successful new treatments to offset an expected decline in revenue as patents expire on key income generators. Sales are growing, however with a reasonable runway for new offerings to hit the market.
In this article, we’ll look at Wall Street sentiment, multiyear price forecasts, and the key factors that are playing a critical role in ABBV’s path going forward.
Current Stock Overview
Market Cap: $383.2 billion
Trailing P/E Ratio: 112.65
Forward P/E Ratio: 16.84
1-Year Return: 9%
2025 YTD: 22%
ABBV has a consensus Buy rating from 28 analysts, according to Benzinga. The average price target is $228.44 per share, which suggests a slight upside from current levels. The highest price target is $284, and the lowest is $190. The three most recent ratings suggest a near-term average target of $258.67, suggesting a 13.30% upside.
Quick Snapshot Table of Predictions & Methodology for Forecasting
|
Year |
Bullish Prediction |
Average Prediction |
Bearish Prediction |
|---|---|---|---|
|
2025 |
$260.6 |
$237.89 |
$222.4 |
|
2026 |
$350.23 |
$298.1 |
$253.49 |
|
2027 |
$333.78 |
$297.76 |
$266.12 |
|
2028 |
$411.33 |
$356.7 |
$311.76 |
|
2029 |
$480.98 |
$408.27 |
$341.27 |
|
2030 |
$568.94 |
$515.99 |
$469.99 |
|
2031 |
$552.12 |
$515.23 |
$482.91 |
|
2032 |
$631.44 |
$575.75 |
$529.59 |
|
2033 |
$718.78 |
$630.15 |
$559.78 |
|
2040 |
$1426.08 |
$1301.27 |
$1196.06 |
|
2050 |
$4361.13 |
$3968.75 |
$3602.6 |
The forecast range in this table is based on algorithmic projections provided by CoinCodex. These models use historical price trends, volatility patterns, and moving averages to estimate future stock prices over multiple time horizons.
Bull & Bear Case
Skyrizi and Rinvoq have made up for Humira’s revenue decline, but AbbVie will face challenges if it doesn’t introduce another moneymaker before the patents for those two drugs expire.
Bull Case
- A strong showing from immunology drugs Skyrizi and Rinvoq is compensating for the sales decline from arthritis treatment Humira, whose patent expired two years ago, and overall revenue has been growing.
- AbbVie has a vast pipeline, which gives it a better chance of producing the next Skyrizi or Rinvoq before their patents expire in the next decade
- AbbVie’s diversified treatments include a neuroscience portfolio with significantly growing sales.
Bear Case
- Almost half of AbbVie’s revenue comes from three drugs, Skyrizi, Rinvoq and Humira, and Humira’s revenue is declining sharply.
- If AbbVie doesn’t find its next moneymaker before key patents expire, it can endure a long downtrend as competitors create copycat products at lower prices.
- AbbVie is $70 billion in debt and has to pay interest with capital that could have gone toward its pipeline, which may limit future growth opportunities.
Stock Price Prediction for 2025
CoinCodex projects AbbVie stock increasing slightly for the rest of the year, with a small chance for a slight loss. The success of Skyrizi and Rinvoq, plus AbbVie’s vast drug pipeline, may make investors comfortable with accumulating shares.
Stock Price Prediction for 2026
CoinCodex anticipates AbbVie posting moderate gains in 2026, with the lowest price target suggesting solid returns. The company’s flagship drugs should continue to perform well, and AbbVie may give encouraging updates about its drug pipeline.
Stock Price Prediction for 2030
CoinCodex projects a very optimistic outlook for ABBV stock in 2030. Its key drugs should continue to perform well, but other key segments like its neuroscience portfolio may propel the stock higher. Skyrizi and Rinvoq must continue to gain market share for AbbVie to realize these forecasts.
Investment Considerations
Most of AbbVie’s sales come from three drugs, but the company is working to diversify revenue. It’s always a race against time for pharma, as expiring patents open the door to more competition and lower margins. Luckily, AbbVie’s key patents don’t expire for several years, giving it enough time to work on various drugs in its pipeline.
AbbVie is also a “Dividend King” that has raised its payout for 53 consecutive years making it attractive to income investors looking for growth. Its current dividend is $1.73 per share with a respectable yield of 3.16%.
